Pramipexole
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Pramipexole is a dopamine agonist used for Parkinson's disease and restless leg syndrome (RLS).[1][2][3] Pramipexole is also sold under the brand names Mirapex and Mirapex ER.[3]
Theory[edit | edit source]
Evidence[edit | edit source]
No clinicial trials have yet been carried out of pramipexole for patients with ME/CFS.
In 2005, Holman et al. found that pramipexole improved fatigue, pain, and overall function in fibromyalgia patients.[4]
Pramipexole has been shown to reduce fatigue in Parkinson's disease.[5]
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
Notable studies[edit | edit source]
- 2005, A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications[4] - (Full text)
See also[edit | edit source]
Learn more[edit | edit source]
- Pramipexole - MedlinePlus
- Pramipexole - StatPearls book
- Pramipexole - WebMD
References[edit | edit source]
- ↑ "Pramipexole". MedlinePlus Drug Information. Retrieved February 21, 2022.
- ↑ Singh, Raman; Parmar, Mayur (2022). Pramipexole. Treasure Island (FL): StatPearls Publishing. PMID 32491471.
- ↑ 3.0 3.1 "Pramipexole Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD". WebMD. Retrieved February 21, 2022.
- ↑ 4.0 4.1 Holman, Andrew J.; Myers, Robin R. (2005). "A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications". Arthritis & Rheumatism. 52 (8): 2495–2505. doi:10.1002/art.21191. ISSN 1529-0131.
- ↑ https://www.jstage.jst.go.jp/article/internalmedicine/50/19/50_19_2163/_article/-char/ja/
